Asia FX muted, dollar weakens slightly ahead of Fed rate decision
Investing.com - Goldman Sachs initiated coverage on Gubra A/S (GUBRA:DC) with a Neutral rating and a price target of DKK520.00 on Friday.
The investment bank cited concerns that Gubra’s growth potential is already reflected in the current valuation, suggesting investors might benefit from waiting for a better entry point.
Goldman Sachs identified GUBamy as the key driver in their financial model, noting they would need additional clarity on the competitive landscape for amylin-based treatments before taking a more positive stance on the stock.
The firm specifically highlighted eloralintide’s Phase 2 data, expected in the second half of 2025, as a potential overhang that could weigh on Gubra’s stock price and establish efficacy benchmarks for the category, though tolerability remains an equally important metric.
Goldman Sachs also pointed to potential stock volatility due to the uncertain timing of updates from Gubra’s pipeline, noting that many of the company’s assets are controlled by partners.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.